SavedAdd your journal

Journals / Viral Hepatitis Journal / 2020 / Cilt: 26 - Sayı: 1

Evaluating The Frequency of Autoantibodies in Patients with Chronic Hepatitis B

Kronik Hepatit B Hastalarında Otoantikor Sıklığının Değerlendirilmesi

Hatice YORULMAZ
Elif YORULMAZ
Ümit Seza TETİKKURT
Ayşe Banu ESEN
Mehmet ÖNCÜ
Umut AYKANAT
Fatma EKŞİ POLAT
Münevver Gül AVŞAR
Pages
14–21
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hepatosteatosislevel of the patient group was significantly lower than the controlgroup, statistically (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The objective of this study is to evaluate the frequencyof autoantibodies retrospectively in newly diagnosed chronichepatitis B (CHB) patients.Materials and Methods: The study was retrospectively conductedin between Jan 2010 and August 2015 in a research and traininghospital in İstanbul with 122 patients (ages of 17-80) consulted toGastroenterology and Infection Diseases and diagnosed with CHBand 117 healthy control group.
📊
Key Findings & Data:In both groups, positive and negativerates of anti-nuclear antibody (ANA), anti-smooth muscle antibody(ASMA), anti-mitochondrial antibody (AMA) and anti-liver-kidneymitochondrial antibody (anti-LKM) were compared.Results: No AMA and LKM1 were observed in any patient orcontrol groups.
💡
Conclusion & Impact:Hepatosteatosislevel of the patient group was significantly lower than the controlgroup, statistically (p
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The objective of this study is to evaluate the frequencyof autoantibodies retrospectively in newly diagnosed chronichepatitis B (CHB) patients.Materials and Methods: The study was retrospectively conductedin between Jan 2010 and August 2015 in a research and traininghospital in İstanbul with 122 patients (ages of 17-80) consulted toGastroenterology and Infection Diseases and diagnosed with CHBand 117 healthy control group. In both groups, positive and negativerates of anti-nuclear antibody (ANA), anti-smooth muscle antibody(ASMA), anti-mitochondrial antibody (AMA) and anti-liver-kidneymitochondrial antibody (anti-LKM) were compared.Results: No AMA and LKM1 were observed in any patient orcontrol groups. ANA result was positive in 9.8% of the patientgroup and 8.5% of the control group; and there was no statisticallysignificant difference between them (p>0.05). ASMA result waspositive in 5.7% of the patient group and 0.9% of the control group;and the difference between them was very close to significance butstatistically not enough to be significant (p>0.05). Hepatosteatosislevel of the patient group was significantly lower than the controlgroup, statistically (p

Özet

Amaç: Bu çalışmada yeni tanı konulmuş kronik hepatit B (KHB) hastalarında otoantikor sıklığını retrospektif olarak değerlendirmek amaçlanmıştır. Gereç ve Yöntemler: Çalışma Ocak 2010-Ağustos 2015 yılları arasında, İstanbul ilindeki bir eğitim araştırma hastanesinin gastroenteroloji ve enfeksiyon hastalıkları polikliniklerine başvuran, KHB tanısı alan 17-80 yaş arası 122 hasta ve 117 sağlıklı kontrol grubu ile retrospektif olarak gerçekleştirilmiştir. Her iki grupta anti-nükleer antikor (ANA), anti-düz kas antikoru (ASMA), anti-mitokondriyal antikorlar (AMA) ve anti-karaciğer-böbrek mitokondriyal antikoru (anti-LKM) pozitiflik ve negatiflik oranları karşılaştırılmıştır. Bulgular: Hasta ve kontrol grubundaki hiçbir olguda AMA ve LKM1 görülmemiştir. Hasta gruptaki olguların %9,8’i ve kontrol grubundaki olguların da %8,5’inde ANA sonucu pozitif olup, aralarında istatistiksel olarak anlamlı bir farklılık bulunmamıştır (p>0,05). Hasta gruptaki olguların %5,7’si ve kontrol grubundaki olguların da %0,9’unda ASMA sonucu pozitif olup; aralarındaki farklılık anlamlılığa çok yakın olmasına karşın istatistiksel olarak anlamlı bulunmamıştır (p>0,05). Hasta grubun hepatosteatoz düzeyi, kontrol grubundan istatistiksel olarak anlamlı düzeyde düşük bulunmuştur (p

🔖

Cite This Article

YORULMAZ, H., YORULMAZ, E., TETİKKURT, Ü. S., ESEN, A. B., ÖNCÜ, M., AYKANAT, U., POLAT, F. E., AVŞAR, M. G. (2022). Evaluating The Frequency of Autoantibodies in Patients with Chronic Hepatitis B. Viral Hepatitis Journal, Cilt: 26 - Sayı: 1, 14–21. https://ajindex.com/articles/646336

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733- 1745
  2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089-2094
  3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107
  4. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN et al. The changing epidemiology of hepatitis B in the UnitedStates. Need for alternative vaccination strategies. JAMA. 1990;263:1218-1222
  5. Fritzler MJ. Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun Rev. 2008;7:616-620
  6. Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4:491-498
  7. Peng Y, Kowalewski R, Kim S, Elkon KB. The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol. 2005;42:781-787
  8. Seçkin Y, Karıncaoğlu M, Cömert M, Ateş F. Prevalence of autoantibody in patients with chronic hepatitis B and C. Cumhuriyet Med J. 2009;31:388-392
  9. Panasiuk A. Autoantibodies in chronic liver diseases. Rocz Akad Med Bialymst. 2001;46:106-112
  10. Volchkova EV, Allenov MN, Umbetova KT, Ivanova IV. Autoimmune manifestations in acute viral hepatitides. Ter Arkh. 2003;75:11-14
  11. Codes L, de Jesus RS, Cunha S, Cruz M, Parana R. Frequency and implications of autoantibodies in acute viral hepatitis. Rev Soc Bras Med Trop. 2002;35:465-469
  12. Tage-Jensen U, Permin H, Hardt F, Juhl E, Mathiesen LR, Nielsen JO, Ranek L. Circulating autoantibodies in patients with acute viral hepatitis. Relation to etiology and clinical course. Scand J Gastroenterol. 1980;5:229-235 13. Afşar I, Şener AG, Kurultay N, Türker M. Kronik HBV ve HCV hastalarında otoantikor prevalansı. Turkiye Klinikleri Tıp Dergisi. 2007;27:649-653
  13. Bayram A, Sözen E, Ekşi F, Karslıgil T, Balcı I. Relationship of anti-nuclear autoantibodies with HBV infection in patients with rheumotological complaints. Turkish Microbiological Society. 2008;38:33-36
  14. Unal F, Genel F, Ozgenç F, Aksu G, Aydogdu S, Kutukçuler N, Yagci RV. Immune status and autoantibody formation in children with chronic hepatitis B infection. Panminerva Med. 2002;44:353-357
  15. Michalska Z, Stalke P, Witczak-Malinowska K, Lakomy EA, Sikorska K, Radowska D, Stolarczyk J, Trocha H. Autoimmune reactions in HBV and HCV. Med Sci Monit. 2001;7:175-180
  16. Zheng R, Chen J, Zhuang Q, Lu Y, Chen J, Chen B. Clinical